Skip to content Skip to footer
Subscribe Now
Astrazeneca
News

UK’s MHRA Approves AstraZeneca’s Trixeo Aerosphere with Near-Zero GWP Propellant for Chronic Obstructive Pulmonary Disease (COPD)

Shots: The UK’s MHRA has approved Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) with HFO-1234ze(E), a next-generation, near-zero global warming potential (GWP) propellant for treating COPD in adults; regulatory review is ongoing in EU, China & other regions Approval was based on a next-generation propellant clinical development program assessing Trixeo + HFO-1234ze(E) vs Trixeo + HFA-134a,…
May 13, 2025

Read more

Viewpoints_Dr. Robert Fogel_Janet Franklin_Dr. Dave Singh
VIEWPOINTS

ATS 2024: Robert Fogel, Janet Franklin, and Dave Singh from AstraZeneca & Amgen in Conversation with PharmaShots

Shots:  Recently AstraZeneca and Amgen presented the results in late-breaking session from the COURSE trial, a proof-of-concept study evaluating tezepelumab in COPD  The PoC study was carried out in people with moderately to very severe COPD with a broad range of eosinophil levels  Today, at PharmaShots we have Robert Fogel from AstraZeneca, Janet Franklin from…
October 8, 2024

Read more

VIEWPOINTS_Andrew Menzies-Gow2_2024
VIEWPOINTS

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Shots  While sharing the details on Fasenra, Andrew highlights the unmet medical need in the healthcare sector as there’s only one approved treatment for EGPA  With mepolizumab as the comparator drug for the trial, Andrew shares the positive results in achieving remission rates. Andrew sheds light on the unique mechanism of benralizumab that directly targets…
December 4, 2023

Read more

Viewpoint_Jonas_Duss_2021
VIEWPOINTS

PharmaShots Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App

In a recent interview with PharmaShots, Jonas Duss, US CEO and Co-Founder at Kaia Health shared his views on the Kaia Health's COPD Pulmonary Rehabilitation App and their collaboration with Chiesi Group to commercialize the app in EU. Shots: Kaia Health signs an exclusive agreement with Chiesi Group to commercialize the Kaia Health COPD Pulmonary Rehabilitation…
January 19, 2021

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]